Zovegalisib [CAS 2733573-94-7]

Zovegalisib (RLY-2608) is an orally active first-in-class allosteric mutant-selective inhibitor of PI3Ka with anti-tumor activity. Zovegalisib inhibits tumor growth in PIK3CA-mutant xenograft mice models with minimal impact on insulin[1][2][3].

[2733573-94-7]

C29H14ClF5N6O2

608.91

O=C1N[C@@H](C2=CC(F)=CC=C2Cl)C(C1=C3)=C(NC(C4=CC(F)=CC(C(F)(F)F)=C4)=O)C=C3C5=C(C#N)N6C(C=C5)=NC=N6

PI3K

10mM

99.2

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

-20°C, 3 years; 4°C, 2 years (Powder)

Room Temperature